Compare Ascendis Pharma A/S (ASND) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Starbucks Corp — how do they compare? Ascendis Pharma A/S trades at $254.87 (market cap $16.67B), while Starbucks Corp trades at $108.14 (market cap $121.59B). The key difference: Starbucks Corp is far larger — about 7.3× Ascendis Pharma A/S's market cap, and Starbucks Corp pays a 2.33% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | SBUX | |
|---|---|---|
Market Cap | $16.67B | $121.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $108.37 |
52-Week Low | $189.74 | $78.46 |
Enterprise Value | $17.04B | $140.42B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.17, down slightly by 0.18% on the day, while maintaining strong analyst support with 92% buy ratings and a $309.75 consensus price target. The company shows impressive revenue growth from $51M in 2022 to $720M in 2025, with profitability improving as net loss narrows to -$228M. Recent technical indicators show a bullish trend with the stock trading near resistance at $255-257, while fundamental metrics reveal high valuation ratios (P/E 29.05, P/S 15.68) offset by exceptional gross margins of 89.04%.
ASND presents a compelling growth story with multiple product launches in rare endocrine diseases driving revenue expansion, though investors face risks from negative shareholder equity and high debt levels. The company's transition to positive operating cash flow ($54M in 2025) and inclusion in Russell indexes signal maturation, but execution risks remain as the stock trades at premium valuations requiring continued strong performance to justify current levels.
Starbucks (SBUX) trades at $107.57, up 2.79% today, showing strong momentum near its 52-week high. The stock benefits from a bullish technical outlook and improved quarterly earnings, with Q2 2026 EPS beating estimates at $0.85 vs. $0.66 expected. Revenue trends are positive, with 2025 revenue reaching $37.18B, though net income margin declined to 5.17%. Recent news highlights a turnaround in traffic and margin expansion, supported by new product launches like carbonated refreshers and seasonal offerings.
The outlook for SBUX is cautiously optimistic, with analyst consensus pointing to a $113.60 price target. Key opportunities include sustained traffic recovery and cost efficiency gains, but risks remain from high valuation (P/E 61.65) and competitive pressures. Investors should weigh the earnings rebound against premium multiples and monitor execution of growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
